Patients are encouraged to disclose all of their medications and medical history to their healthcare providers to avoid drug interactions and report any side effects
Signs include widespread hives (not just at the injection site), difficulty breathing, swelling of the face or throat, rapid heartbeat, or severe dizziness
Your body chemistry, weight loss goals, and any underlying health conditions all play a role in determining which medication may work best for you, whether its semaglutide, tirzepatide, or any other weight loss drug
Novo Nordisk expects to submit marketing authorisation applications in the US and EU in the first half of 2025
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes